ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
Home
Press release
May 27, 2021 11:00 JST
Source:
Avance Clinical
Avance Clinical Releases Industry Survey Results at BIO Korea 2021
Data Quality the Top Criteria for Selecting a CRO
ADELAIDE, AUS, May 27, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient Avance Clinical shared results of a recent industry survey conducted by the company that found data quality to be the most important criteria for selecting a CRO for Phase ll studies in Australia.
Results from the survey found 63.64% of respondents selected data quality as the Key operational consideration when planning Phase II, followed by access to patients, then CRO therapeutic area expertise, cost, and access to KOLs.
Avance Clinical is attending BIO Korea 2021 virtually and is available via the Partnering platform to discuss the benefits of conducting trials in Australia. Avance Clinical has extensive experience in conducting trials in oncology, CNS, cardiovascular, infectious diseases and dermatology.
Avance Clinical CEO, Yvonne Lungershausen, said South Korea is recognised globally for its thriving biotech sector and the CRO is keen to connect with companies wanting regional alternatives for their clinical development. "As Australia's CRO for biotechs, we are seeing an increasing number of South Korean biotechs selecting Australia to accelerate their Phase I and II trials," she said. "The high-quality of our data for FDA and other regulatory authority approvals is a key factor in the decision-making process."
The clinical trial environment in Australia supports rapid startup and a rebate of more than 40% on clinical costs as part of the Australian Government's clinical trial attraction incentive program.
In addition, Avance Clinical is accredited by the Office of the Gene Technology Regulator (OGTR) so it can manage gene technology trials in Australia.
This accreditation recognizes that Avance Clinical has the CRO resources and internal processes in place to effectively manage pre-clinical and clinical trials for products involving genetically modified organisms (GMOs).
Take the Quiz: Test your Knowledge about Australian Clinical Trials here.
https://www.surveymonkey.com/r/Australian-Clinical-Trials
About Avance Clinical
Avance Clinical, Australia's CRO for biotechs, has more than 20-years of experience providing excellence in clinical research services for biotech companies from around the globe. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field. Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class investigators and sites able to access specific patient groups. Visit
http://www.avancecro.com
for more information.
Recent Awards:
Excellence in Business Award 2021
Frost & Sullivan Asia-Pacific CRO Market Leadership Award 2020
Other benefits of working with Avance Clinical include:
1. The Government R&D grant offers up to 43.5% rebate on clinical trial spend
2. COVID-19 clinical continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class investigators and sites
7. Access to sites/Phase I facilities with established healthy subject databases and specific patient populations
8. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
9. Seasonal studies: Northern hemisphere sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons
Media Contact:
media@avancecro.com
Source: Avance Clinical
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Mazda to Strengthen Production and Sales Systems in Thailand
Feb 14, 2025 17:04 JST
Toyota Develops New Fuel Cell System
Feb 14, 2025 15:27 JST
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 14, 2025 12:09 JST
Nissan, Honda and Mitsubishi Motors terminate MOU regarding consideration of tripartite collaboration
Feb 13, 2025 16:20 JST
ANA InterContinental Tokyo unveils Icon Reborn transformation
Feb 13, 2025 15:00 JST
MHI Thermal Systems Receives Top Honors on Australia's Foremost Consumer Review Platform for Two Series of Split System Air-Conditioners
Feb 13, 2025 12:47 JST
Honda Presents World Premiere of Seven Refreshed Large-size Outboard Motors at the Miami International Boat Show 2025
Feb 13, 2025 10:50 JST
Fujitsu to offer Fujitsu Cloud Service Generative AI Platform for secure and flexible enterprise data management
Feb 13, 2025 10:01 JST
ULVAC Develops Roll-to-Roll Lithium Deposition System, Unveiling at Battery Japan
Feb 13, 2025 08:30 JST
Mitsubishi Power Secures Major Gas Turbine and Services Order for Al Wahda Open Cycle Gas Turbine Power Plant in Morocco
Feb 12, 2025 16:21 JST
MHI Delivers Final 7000-Series AGT Trainset for the Astram Line
Feb 12, 2025 12:24 JST
Fujitsu and Yokohama National University achieve world's first real-time prediction of tornadoes associated with typhoons using supercomputer Fugaku
Feb 12, 2025 11:37 JST
NEC Solution Modernizes Network Infrastructure Construction Work
Feb 10, 2025 15:05 JST
Olympus Recognized on CDP's "A List", the Highest Rating in the Field of Climate Change
Feb 10, 2025 11:00 JST
uSMART Capital, LLC officially approved for U.S. FINRA license
Feb 07, 2025 17:40 JST
TANAKA to Provide Medals for the Tokyo Marathon 2025 That Represent All the Participants in the Event with Woven Lines
Feb 07, 2025 04:00 JST
MHI Thermal Systems to Launch New Model of the "Ene-Conductor" Heat Source Control System
Feb 06, 2025 16:51 JST
Hitachi establishes its fourth Corporate Venture Capital Fund to capture technology turning points and future growth opportunities
Feb 06, 2025 16:32 JST
Approval in Principle (AiP) Acquired from Classification Society for Low-Pressure Type Coastal Liquefied CO2 Carrier
Feb 05, 2025 17:46 JST
Toyota Powers On New North Carolina Automotive Battery Plant
Feb 05, 2025 13:59 JST
More Latest Release >>
Related Release
Avance Clinical Appoints Asia Regional Director as Part of Global Expansion Program
July 23 2024 16:00 JST
New Research Launched at BIO24 Finds CROs with In-house Regulatory Affairs Can Deliver 30% Savings, Halve Timelines and Cut Risks for Biotechs
June 04 2024 22:00 JST
Avance Clinical Expands Specialist CNS, Cardiometabolic, and Rare Diseases CRO Services in Europe with Julius Clinical
May 31 2024 16:00 JST
Avance Clinical Expands Further into APAC with New Clinical Operations in South Korea
May 08 2024 09:00 JST
Avance Clinical Showcases Clinical Excellence at World Orphan Drug Conference in Boston, April 23-25
April 19 2024 16:00 JST
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 Study
March 28 2024 14:42 JST
Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report
February 28 2024 08:00 JST
Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner
January 12 2024 16:00 JST
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US
October 19 2023 09:00 JST
Avance Clinical at ASCO & BIO 2023: Early Phase Oncology Trials Increasingly Elaborate and Demand More Patients
May 30 2023 10:00 JST
More Press release >>